MA44119A - Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale - Google Patents
Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinaleInfo
- Publication number
- MA44119A MA44119A MA044119A MA44119A MA44119A MA 44119 A MA44119 A MA 44119A MA 044119 A MA044119 A MA 044119A MA 44119 A MA44119 A MA 44119A MA 44119 A MA44119 A MA 44119A
- Authority
- MA
- Morocco
- Prior art keywords
- adeno
- treatment
- viral vectors
- associated viral
- spinal amyotrophy
- Prior art date
Links
- 208000002320 spinal muscular atrophy Diseases 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6027—Vectors comprising as targeting moiety peptide derived from defined protein from viruses ssDNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267012P | 2015-12-14 | 2015-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44119A true MA44119A (fr) | 2018-10-31 |
Family
ID=57737990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044119A MA44119A (fr) | 2015-12-14 | 2016-12-14 | Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180353624A1 (enExample) |
| EP (1) | EP3394270A1 (enExample) |
| JP (1) | JP7082050B2 (enExample) |
| KR (1) | KR20180086266A (enExample) |
| CN (1) | CN109072254A (enExample) |
| AU (1) | AU2016370630B2 (enExample) |
| BR (1) | BR112018011975A2 (enExample) |
| CA (1) | CA3008280A1 (enExample) |
| IL (1) | IL259877A (enExample) |
| MA (1) | MA44119A (enExample) |
| MX (1) | MX2018007234A (enExample) |
| WO (1) | WO2017106354A1 (enExample) |
| ZA (1) | ZA201803956B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190160187A1 (en) * | 2016-07-26 | 2019-05-30 | Cornell University | Gene therapy for the treatment of aldehyde dehydrogenase deficiency |
| RS65241B1 (sr) | 2017-02-28 | 2024-03-29 | Univ Pennsylvania | Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe |
| JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
| JP2020533968A (ja) * | 2017-08-25 | 2020-11-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 組換えアデノ随伴ベクター |
| JP2021534154A (ja) * | 2018-08-15 | 2021-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脊髄性筋萎縮症のための併用療法 |
| US20220042045A1 (en) * | 2018-12-21 | 2022-02-10 | Genethon | Expression cassettes for gene therapy vectors |
| EP4013387A4 (en) * | 2019-08-15 | 2023-09-27 | Biogen MA Inc. | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY |
| CN112011571A (zh) * | 2020-04-26 | 2020-12-01 | 辉大(上海)生物科技有限公司 | 一种用于治疗脊髓性肌萎缩的基因治疗药物 |
| US20230173102A1 (en) * | 2020-04-28 | 2023-06-08 | Genethon | Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders |
| IL298138A (en) | 2020-05-12 | 2023-01-01 | Univ Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| RU2742837C1 (ru) * | 2020-06-02 | 2021-02-11 | Общество С Ограниченной Ответственностью "Анабион" | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок SMN1, и ее применение |
| CN113755524B (zh) * | 2020-06-02 | 2023-11-03 | 舒泰神（北京）生物制药股份有限公司 | 用于治疗脊髓性肌萎缩的腺相关病毒载体及其用途 |
| WO2022119826A1 (en) * | 2020-12-01 | 2022-06-09 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of peripheral myelin protein-22 |
| CN117545842A (zh) * | 2021-01-29 | 2024-02-09 | 拜奥卡德联合股份公司 | SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应 |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| CN112852882A (zh) * | 2021-02-04 | 2021-05-28 | 中吉智药(南京)生物技术有限公司 | 一种杆状病毒感染昆虫细胞生产aav基因药物的系统及方法 |
| IL312487A (en) * | 2021-11-09 | 2024-07-01 | Asimov Inc | Stable production systems for adeno-associated virus vector production |
| WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
| KR102717399B1 (ko) * | 2022-05-10 | 2024-10-16 | 서울대학교산학협력단 | 인간 smn1 단백질 변이체 및 이의 용도 |
| WO2024165839A1 (en) * | 2023-02-06 | 2024-08-15 | Royal Holloway And Bedford New College | Transgenes |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1668143B1 (en) * | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| CN104704123A (zh) * | 2012-06-21 | 2015-06-10 | 肌肉学研究协会 | 基因治疗载体的广泛的基因递送 |
| BR112015027336A2 (pt) * | 2013-05-01 | 2017-09-26 | Genzyme Corp | composições e processos para tratamento de atrofia muscular espinhal |
| AU2014340149B2 (en) * | 2013-10-22 | 2020-12-24 | Shire Human Genetic Therapies, Inc. | CNS delivery of mRNA and uses thereof |
| GB201403684D0 (en) * | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP4134375A1 (en) * | 2015-07-30 | 2023-02-15 | Massachusetts Eye & Ear Infirmary | Ancestral adeno associated virus sequences and uses thereof |
-
2016
- 2016-12-14 AU AU2016370630A patent/AU2016370630B2/en not_active Expired - Fee Related
- 2016-12-14 CN CN201680081819.2A patent/CN109072254A/zh active Pending
- 2016-12-14 MA MA044119A patent/MA44119A/fr unknown
- 2016-12-14 MX MX2018007234A patent/MX2018007234A/es unknown
- 2016-12-14 BR BR112018011975A patent/BR112018011975A2/pt not_active Application Discontinuation
- 2016-12-14 JP JP2018531163A patent/JP7082050B2/ja not_active Expired - Fee Related
- 2016-12-14 CA CA3008280A patent/CA3008280A1/en active Pending
- 2016-12-14 EP EP16822581.1A patent/EP3394270A1/en not_active Withdrawn
- 2016-12-14 WO PCT/US2016/066669 patent/WO2017106354A1/en not_active Ceased
- 2016-12-14 KR KR1020187019828A patent/KR20180086266A/ko not_active Withdrawn
- 2016-12-14 US US16/061,109 patent/US20180353624A1/en not_active Abandoned
-
2018
- 2018-06-07 IL IL259877A patent/IL259877A/en unknown
- 2018-06-13 ZA ZA2018/03956A patent/ZA201803956B/en unknown
-
2021
- 2021-09-30 US US17/490,611 patent/US20220265861A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016370630A1 (en) | 2018-06-28 |
| JP7082050B2 (ja) | 2022-06-07 |
| CA3008280A1 (en) | 2017-06-22 |
| US20220265861A1 (en) | 2022-08-25 |
| MX2018007234A (es) | 2018-11-09 |
| IL259877A (en) | 2018-07-31 |
| ZA201803956B (en) | 2019-04-24 |
| JP2018537984A (ja) | 2018-12-27 |
| AU2016370630B2 (en) | 2023-04-13 |
| EP3394270A1 (en) | 2018-10-31 |
| US20180353624A1 (en) | 2018-12-13 |
| KR20180086266A (ko) | 2018-07-30 |
| CN109072254A (zh) | 2018-12-21 |
| WO2017106354A1 (en) | 2017-06-22 |
| BR112018011975A2 (pt) | 2018-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47688A (fr) | Compositions utiles dans le traitement de l'amyotrophie spinale | |
| HUE071243T2 (hu) | Mikro-disztrofin bejuttatása adeno-asszociált vírus vektorral izomdisztrófia kezelésére | |
| EP3442600A4 (en) | ADENOASSOZED VIRUS VECTOR ADMINISTRATION OF B-SARCOGLYCAN AND MICRORNA-29 AND TREATMENT OF MUSCLE DYSTROPHY | |
| EP3419981A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| MA45192A (fr) | Traitement d'association | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| EP3370617A4 (en) | NON-INVASIVE ILLUSTRATION AND TREATMENT SYSTEM FOR CARDIAC ERRORS | |
| EP3471780A4 (en) | TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| EP3504187A4 (en) | USE OF PRIDOPIDIN FOR THE TREATMENT OF FUNCTIONAL DECAY | |
| EP2978373A4 (en) | SYSTEM FOR USE IN THE TREATMENT OF SPINE FRACTURES | |
| EP3288957A4 (en) | NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER | |
| EP3403675A4 (en) | ADENO-ASSOCIATED VIRUSVIRION FOR USE IN THE TREATMENT OF EPILEPSIA | |
| MA45492A (fr) | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène | |
| HUE060496T2 (hu) | Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére | |
| EP3735970C0 (en) | CEBRANOPADOL FOR THE TREATMENT OF PAIN IN PATIENTS WITH DECREASED LIVER AND/OR KIDNEY FUNCTION | |
| EP3848022C0 (en) | THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION | |
| EP3424404A4 (en) | OPHTHALMOLOGICAL IMAGING DEVICE | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| MA43106A (fr) | Traitement de l'oligo-ovulation associée à la stéatose hepatique | |
| IL281083A (en) | Adeno-associated viral vectors for the treatment of best disease | |
| EP3442538A4 (en) | TREATMENT OF EXTRAPYRAMIDAL SYNDROME WITH TRAPIDILE | |
| EP3411062A4 (en) | USE OF CD24 PROTEINS FOR THE TREATMENT OF LEPTIN DEFICIENT DISORDERS | |
| EP3423060A4 (en) | IMATINIB FOR USE IN THE TREATMENT OF STROKE | |
| EP3337475A4 (en) | NITROXIDE WITH AMYLOID BINDING AGENT FOR IMAGING AND THERAPEUTIC USES |